The scope of genetic testing continues to evolve, yet in hematologic malignancies, Andrew Laramore, MD, says that it is difficult to determine which patients should be tested and how panels should be best utilized.
“Nobody has a clear-cut answer as to whether everybody should get tested, or whether it should be done on a case-by-case basis, said Laramore, a pathologist at Diagnostic Pathology Services.
While genetic tests on patients with chronic myeloid leukemia (CML) may be positive for BCR-ABL1
, a molecular driver for the disease, there are other mutations that may show up on panels in which practitioners are unsure if they are related to the disease or not, he added.
... to read the full story